depressionFull doseFullModerate evidence

Psilocybin edged past placebo in treatment-resistant depression

258 people, a hit primary endpoint, and a company press release rather than a paper.

2025Published
Phase 3 trial, reported by company press releaseStudy type
258 peopleSample
What our evidence ratings mean

What they did

Compass Pathways ran a phase 3 trial of a single 25mg dose of its synthetic psilocybin across thirty-two US sites in people with treatment-resistant depression, measuring depression scores at six weeks.

What they found

The company reported the trial met its primary endpoint, with a 3.6 point advantage over placebo on the MADRS depression scale at week six.

258participants
3.6 ptsadvantage over placebo
Not peer reviewedas of this writing

Worth knowing

This is a corporate press release dated June 2025, not a published paper. It has not been peer reviewed and the full data have not been released. A 3.6 point MADRS difference is statistically clear and clinically modest. Treat it as news, not as evidence.

Compass Pathways. Phase 3 COMP005 trial results, company press release, June 2025.

Read the source

Keep reading

depressionOnly the highest dose eased treatment-resistant depressiondepressionIn ordinary depression, psilocybin beat placebo by twelve pointsdepressionPsilocybin and a standard antidepressant, with no clear winner

Every trial in this section used a single large dose, given in a clinic, with trained people in the room for the whole session. That is a different activity from anything sold on this site. More on why that distinction matters.

Browse the library

Microdosing 8Depression 9Anxiety 6Addiction 9Cognition 6Ageing and injury 3Brain and plasticity 7Other conditions 9Safety 6All research 63

For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.